Published in:
01-08-2017 | Chest
Development and validation of a prediction model for measurement variability of lung nodule volumetry in patients with pulmonary metastases
Authors:
Eui Jin Hwang, Jin Mo Goo, Jihye Kim, Sang Joon Park, Soyeon Ahn, Chang Min Park, Yeong-Gil Shin
Published in:
European Radiology
|
Issue 8/2017
Login to get access
Abstract
Objectives
To develop a prediction model for the variability range of lung nodule volumetry and validate the model in detecting nodule growth.
Materials and methods
For model development, 50 patients with metastatic nodules were prospectively included. Two consecutive CT scans were performed to assess volumetry for 1,586 nodules. Nodule volume, surface voxel proportion (SVP), attachment proportion (AP) and absolute percentage error (APE) were calculated for each nodule and quantile regression analyses were performed to model the 95% percentile of APE. For validation, 41 patients who underwent metastasectomy were included. After volumetry of resected nodules, sensitivity and specificity for diagnosis of metastatic nodules were compared between two different thresholds of nodule growth determination: uniform 25% volume change threshold and individualized threshold calculated from the model (estimated 95% percentile APE).
Results
SVP and AP were included in the final model: Estimated 95% percentile APE = 37.82 · SVP + 48.60 · AP-10.87. In the validation session, the individualized threshold showed significantly higher sensitivity for diagnosis of metastatic nodules than the uniform 25% threshold (75.0% vs. 66.0%, P = 0.004)
Conclusion
Estimated 95% percentile APE as an individualized threshold of nodule growth showed greater sensitivity in diagnosing metastatic nodules than a global 25% threshold.
Key Points
• The 95 % percentile APE of a particular nodule can be predicted.
• Estimated 95 % percentile APE can be utilized as an individualized threshold.
• More sensitive diagnosis of metastasis can be made with an individualized threshold.
• Tailored nodule management can be provided during nodule growth follow-up.